References
- Warpehoski M A. CC-165 analogs: Therapeutic potential of a sequence specific drug-DNA reaction. Proc Am Assoc Cancer Res 1989; 30: 668
- Warpehoski M A. Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J Med Chem 1988; 31: 3
- Chidester C G, Krueger W C, Mizsak S A. The structure of CC-1065, a potent antitumor agent, and its binding to DNA. J AmChem Soc 1981; 103(25)7629–7635
- Hurley L H, Warpehoski M A, Lee C S. Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogs. J Am Chem Soc 1990; 112(12)4633–4649
- DeKoning T F, Kelly R C, Wallace T L. Antitumor activity and biochemical effect of three selected cyclopropapytroloindole (CPI) analogs. Proc Am Assoc Cancer Res 1989; 30: 491, abstract 1953
- DeKoning T, Postmus F. RJ., Wallace T L. Therapeutic evaluation of three cyclopropapyrroloindole (CPI) analogs against human tumor xenografts. Proc Am Assoc Cancer Res 1990; 31: 348
- Hurley L H, Needham-VanDevanter D R. Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo(1,4)benzodiazepines. Acc Chem Res 1986; 19(8)203–237
- Hanka L J, Dietz A, Gerpheide S A. CC-1065 (NSC 298223). a new antitumor antibiotic. Production, in vitro, biological activity. microbiological assay. and taxonomy of the producing organism. J Antibiot 1978; 31: 1211
- Martin D G, Hanka L J, Neil G L. Isolation. characterization. and preliminary antitumor evaluation of CC-1065, a potent new agent from fermentation. Proc Am Assoc Cancer Res 1978; 19: 99
- Martin D G, Chidester C G, Ducharnp D J. Structure of CC-1065 (NSC 298223). a new antitumor antibiotic. 1. Antibiot 1980; 33: 902
- Martin D, Biles G. C, Gerpheide S A. CC-1065 (NSC 298223), a potent new antitumor agent. Improved production and isolation, characterization, and antitumor activity. J Antibiot 1981; 34: 1119
- Reynolds V L, McGovren J P, Hurley L H. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J Antibiot 1986; 39: 319
- Wierenga W, Bhuyan B K, Kelly R C. Antitumor activity and biochemistry of novel analogs of the antibiotic CC-1065. Adv Enzyme Regul 1986; 25: 141
- McGovren J P, Clarke G L, Pratt E A. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot 1984; 37(1)63–70
- DeKoning T FK, Neger W C, Wallace T L. Influence of structure and chirality on the antitumor activity and biochemical effects of CC-1065 and its analogs. Proc Am Assoc Cancer Res 1987; 28: 262
- Warpehoski M A, Kelly R C, McGovren P. N-2-substituted tetrahydro-4-oxocyclopropa[c]pyrrolo-[3,2-e]indoles: Novel an-ticancer agents modeled on CC-1065. Proc Am Assoc Cancer Res 1985; 26: 221, abstract
- Mitchell M A, Johnson P D, Williams M G. Interstrand DNA cross-linking with dimers of the spirocyclopropyl alkylating moiety of CC-1065. J AmChem Soc 1989; III(16)6428–6429
- McGovren J, Kelly P. RC., Aristoff P A. Cyclopropapyrroloindole (CPI) dimers: Sequence specific DNA binding bis-al-kylators. Proc. of NCl/EORTC Symposium on New Drugs and Cancer Therapy, Abstract 397. 1989
- Alberts D, Chen G. Tabular Summary of Pharmacokinetic Parameters Relevant to In Vitro Drug Assay, in Cloning Human Tumor Stem Cells, S Salmon. Alan R Liss, New York 1980; 351–359
- Petru E, Sevin B U, Perras J. Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol 1990; 38: 155–159
- Sevin B U, Peng Z, Perras J. Application of an ATP-bio-luminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988; 31: 191–204
- Chou T, Talaly P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55